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Abstract An effective method of construction of a linear
estimator of AUC in the finite interval, optimal in the
minimax sense, is developed and demonstrated for five PK
models. The models may be given as an explicit C(t) rela-
tionship or defined by differential equations. For high
variability and rich sampling the optimal method is only
moderately advantageous over optimal trapezoid or stan-
dard numerical approaches (Gauss-Legendre or Clenshaw-
Curtis quadratures). The difference between the optimal
estimator and other methods becomes more pronounced
with a decrease in sample size or decrease in the vari-
ability. The described estimation method may appear use-
ful in development of limited-sampling strategies for AUC
determination, as an alternative to the widely used
regression-based approach. It is indicated that many alter-
native approaches are also possible.
Keywords AUC  Optimal sampling theory  Limited
sampling strategy  Quadrature  Estimation  Minimax 
Bioequivalence
Introduction
The estimation of integral of a function, or area under the
curve (AUC), plays an important role in biomedicine
including in pharmacokinetic (PK) or toxicokinetic studies
that are designed to estimate the integral of concentration
of the investigated compound in plasma or tissue taken
over time in a given interval.
AUC ¼
Z t2
t1
C tð Þdt
Within the framework of linear compartmental models
AUC established after an intravenous administration is
used to calculate the drug clearance. Regardless of which
one of the possible linear models is valid, the result is
determined solely by the drug dose and AUC. This is one
of the reasons for AUC to be a central concept of the so-
called model-independent pharmacokinetics. Regulatory
institutions use AUC as a measure of extent of absorption
in order to assess a bioequivalence of different formula-
tions of the same drug [1–3].
Many authors have addressed the problem of practical
determination of AUC. A few papers contain reviews of
numerous algorithms designed to estimate this parameter
[4, 5]. Their authors do not pay any particular attention to
the choice of sampling times, assuming they are given a
priori, maybe following a certain traditional pattern. On the
other hand, several authors have investigated the optimal
designs which should yield the most accurate results using
specific approaches.
The optimal sampling is especially important if the
number of measured concentrations is limited due to
ethical and economical reasons. Duffull et al. searched for
the optimal design with limited sampling for the log-
trapezoid rule applied to the two-exponential equation [6].
A vast number of authors (MEDLINE reports about 200
papers [7]) developed limited sampling strategies for
estimating AUC either of specific drugs, for instance
cyclosporine [8, 9] or midazolam [10], or in the general
situation [11].
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Katz and D’Argenio found optimal sampling times for
estimating the integral of bi- and triexponential equations
using the trapezoid rule [12]. In their original form these
results are of limited usefulness, since the authors have
assumed fixed values of parameters of those equations. In
practice such parameters are more or less uncertain (if they
were certain then the exact AUC would also be known and
no estimation would be necessary). The present paper
extends, in several directions, the ideas of that work.
Namely, the aims of this work are threefold:
1. Find an optimal sample schedule design for trapezoid
rule under parameter uncertainty.
2. Find an optimal quadrature within the class of linear
combination (LC) quadrature approximations [13].
This is to be achieved by simultaneous adjustment of
both sampling design and coefficients (weights) of
quadrature.
3. Evaluate obtained quadratures for five common PK
models by means of simulation.
In order to reach these aims it is required to:
1. set up transparent criteria of optimality;
2. state necessary assumptions to make the problem
tractable;
3. express it as an optimization problem (in this case a
minimax problem);
4. invent an approach to practically solve this optimiza-
tion problem;
5. implement it (as a numerical analysis task);
6. plan and execute optimum searches and simulations;
7. evaluate the results.
These points would be reported in the following sections
after introducing the necessary background.
Method
Background: theory of point estimation
While concepts to be introduced here are quite general
elements of a statistical decision theory, the presentation
will focus on their application to the theory of point esti-
mation or, even more specifically, to the estimation of AUC
in PK models. Let h be a vector of standard (primary) PK
parameters. True AUC may be expressed as a function of
these parameters, AUCðhÞ.
An estimator of an unknown quantity is a function of
observations that in some way approximates that quantity.
As any experiment suffers from various nuisance factors,
the observations do not follow any deterministic model
exactly. Thus the estimation can be imperfect. One may
intuitively expect that certain estimators can perform better
than others. However, if one would like to transform this
intuition into a scientific method, a rigorous criterion is
needed that would enable comparison of estimators.
Towards this end, a statistical theory of point estimation
[14] introduces a loss function LðQ̂; hÞ to assess the pre-
cision of an estimator Q̂. A loss function is always non-
negative and it should yield 0 if an estimation is exact, i.e.
if Q̂ ¼ AUCðhÞ: A quadratic loss function
LðQ̂; hÞ ¼ Q̂ AUC hð Þ
 2
is a typical choice, and it is one of two that will be considered
here. The intuition behind this concept is rather simple: a
wrong estimation causes a loss. The worse the estimate is, the
higher the loss will be. Or: the closer the estimator value to
the true AUC is, the lower the loss will be.
Another important concept is that of risk function. It is
defined as an expectation of a loss. The expectation is taken
over a joint probability distribution of all ei.
R hð Þ ¼ E LðQ̂; hÞ
 
The expectation of a continuous random variable X is
defined as the first moment of its probability density
function uðxÞ:
E X½  ¼
Z
xuðxÞdx
While this definition might appear somewhat abstract, the
expectation has quite simple interpretation, due to a fun-
damental law of statistics: The Law of Large Numbers. If
one repeatedly observes a quantity that is random, then the
average result should tend to the expectation of that
quantity (for a rigorous formulation of that law refer to any
textbook on statistics, e.g. [15]). Thus, if one were to repeat
estimation with a given estimator, then the average loss
should tend to that estimator’s risk.
Estimators may be compared on a basis of their risk.
Unfortunately, there is no estimator which is better than
any other estimator for any parameter vector h [14].
Nonetheless, an optimal estimator in that sense (called a
uniformly optimal estimator) could be found if some
restrictions were applied to the class of considered esti-
mators. Perhaps the most popular one is the case of unbi-
ased estimators with quadratic loss function. They are
called minimum variance unbiased estimators (MVUE).
There can be little benefit from MVUE in pharmacoki-
netics, however, as unbiased estimators do not exist for
standard PK models with usual parameters (or, at least,
they remain unknown).
Despite these problems, a good or even the best esti-
mator, according to reasonable criteria, can be constructed
in a somewhat different manner. The choice between two
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standard solutions depends on whether h is treated as a
random variable with known distribution or as an unknown
parameter. In the first case an estimator that minimizes
expectation of the risk (over h distribution) is searched for.
It corresponds to a Bayesian approach. In the second case a
maximum possible risk is minimized. That is a minimax
problem.
The former approach requires a knowledge of statistical
distribution of PK parameters, while in the second method
one needs to only know the range of those parameters. In
what follows, the latter choice is analysed in detail.
Approach of Katz and D’Argenio
The trapezoid rule may be expressed by the following
equation
Q ¼
Xn
i¼0
wiCðtiÞ; ð1Þ
where
w0 ¼
t1  t0
2
; wi ¼
tiþ1  ti1
2
; i ¼ 1; . . .; n 1;
wn ¼
tn  tn1
2
:
ð2Þ
In practice, an integral is calculated based on measured
concentrations. Assume the integrand follows a certain PK
model with a parameter vector h. Thus, what is measured
can be expressed by the equation:
Ĉi ¼ C ti; hð Þ þ ei
where ei is a random error. The result
Q̂ ¼
Xn
i¼0
wiĈi
is therefore a random variable. It may be considered as a
linear estimator of an unknown integral AUC.
In their paper Katz and D’Argenio proposed ‘‘selecting
observation times so to minimize the expected value of the
squared difference between the estimator and the exact
value of the integral’’. These authors assumed specific
parameters of a multiexponential equation (i.e. they fixed
h) and numerically found a minimum over a vector of
sampling times, t:
min
t
EðQ̂ AUCÞ2: ð3Þ
In terms of previous subsection a sampling schedule that
minimizes the risk of trapezoid rule estimator was found.
In order to include a variance model of ei they used the
decomposition of the expectation of the squared error into a
variance of estimator and its squared bias
E Q̂ AUC
 2h i ¼ V Q̂ þ AUC  E Q̂  2; ð4Þ
the well-known result (for derivation see, for instance,
Lehmann [14] or Katz and D’Argenio [12]). If all ei are
independently distributed with the mean 0 and variance r2i ,
then
E Q̂
 
¼
Xn
i¼0
wiC tið Þ ð5Þ
V Q̂
 
¼
Xn
i¼0
w2i r
2
i ð6Þ
Note that detailed knowledge of the statistical distribution
of ei is not required; any distribution with existing and
known variance can be accepted. One way to make r2i
known is to express it as a function of C. The hetero-
schedastic model with a constant coefficient of variation
(cv) is often assumed in PK models. It will be followed in
the present study.
ri ¼ cvC ti; hð Þ ð7Þ
As the specific values of parameters need to be assumed,
AUC may be calculated based on them and there is no need
to use concentrations at all. Katz and D’Argenio made a
rudimentary analysis of how the precision of the trapezoid
method in an optimal setting changes while changing some
(not all) parameters. It may be done in a more systematic
manner within the framework of minimax approach and
this will be one extension the present paper makes to the
ideas of Katz and D’Argenio.
Optimal sample schedule design
Using the minimax approach the minimization of the risk
for a given h should be replaced by minimization of the
maximum risk that can be obtained for any possible vector
of parameters. Thus the problem in Eq. 3 should be
rewritten as
min
t
max
h
RðhÞ ¼ min
t
max
h
E Q̂ AUCðhÞ
 2h i
:
For highly variable drugs it might be more useful to min-
imize a relative rather than an absolute error. This corre-
sponds to the division of the loss function L by the squared
AUCðhÞ.
LrðQ̂; hÞ ¼
Q̂ AUC hð Þ
 2
AUC hð Þ½ 2
An optimum based on the above loss function (let it be
called relative, in contrast to an absolute function L) will be
analysed in the present study. The corresponding risk
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function will be denoted by RrðhÞ and an expression for the
required optimum takes on the form:
min
t
max
h
RrðhÞ ¼ min
t
max
h
E
Q̂ AUCðhÞ
AUC hð Þ
 !22
4
3
5:
In bioequivalence studies AUC is being compared on a
logarithmic scale; equivalently the comparison focuses on
ratios and not differences of AUC values. Also, in clinical
application, an estimation error of 10 units is certainly
more important if the true AUC equals 50 units than in a
case when it is as large as 300. In both situations use of a
relative risk would be preferable over an absolute risk.
Substituting Eqs. 5 and 6 into Eq. 4 and taking into
account Eq. 7 yields a useful expression for the risk
function that is a subject of minimax optimization:
RrðhÞ ¼ c2v
Xn
i¼0
w2i ½Cðti; hÞ
2þ
(
þ AUCðhÞ 
Xn
i¼0
wiCðti; hÞ
" #29=
;
= AUCðhÞ½ 2
ð8Þ
This is a nested problem: there is a maximization overh within
a minimization over t. It means that for each trial sampling
schedule the maximization inh has to be conducted and finally
that sampling schedule which yielded the smallest maximum
is to be chosen. An optimization is constrained on both levels:
PK parameter values should stay within a reasonable range;
sampling times should be arranged in ascending order and
they should be included in the integration interval. This con-
strained optimization problem cannot be solved analytically
and an application of numerical algorithms is required. The
optimization seems to be one of the most difficult branches of
numerical analysis. There is always the possibility that the
solution found would appear suboptimal. In order to minimize
this possibility, the advanced methods are required using as
much information as is available. This is especially important
on an inner level: unstable results may mislead outer level
optimization routine and thwart convergence.
The necessary information includes first and second
derivatives of the inner objective in h, since they describe
important geometrical properties of the hypersurface along
which the maximum is searched for. The first derivative,
i.e. the gradient, is a local measure of the descent of the
surface, while the second derivative (the Hessian) is a
measure of the local curvature. More details are given in a
subsection on numerical methods.
Optimal quadrature design
Another dimension in which the described approach can be
improved on is the choice of a quadrature. Trapezoid and
log-trapezoid rules are the simplest approaches to
determine AUC. Their drawbacks were frequently indi-
cated [16, 17]. In the present work not only sampling points
are free parameters. Some additional freedom is allowed
regarding the choice of a quadrature. This may be done by
considering a certain class of quadratures parameterized in
a reasonable manner. Here the class of LC methods, as
previously introduced by the present author [13], will be
considered.
The LC-type quadrature by definition has the form given
by Eq. 1, but wi can now be arbitrary; they do not need to
satisfy Eq. 2. ti are knots of the quadrature and wi are its
weights.
Surprisingly, many approaches used in pharmacokinet-
ics belong to this class. In particular, linear trapezoidal,
hyperbolic trapezoidal [18], Lagrange [19] and spline [4]
methods all are of the LC type. The same applies to other
popular general methods of numerical analysis, like New-
ton-Côtes, Gauss-Legendre (GL) or Clenshaw-Curtis (CC)
quadratures [20].
Allowing weights vector w as well as knots vector t to be
manipulated, results in a final statement for the minimum
that should be reached by the optimal method:
min
w;t
max
h
RrðhÞ ¼ min
w;t
max
h
E
Q̂ AUCðhÞ
AUCðhÞ
 !22
4
3
5:
Equation 8 remains valid.
In this problem a maximization over h is nested within a
minimization in both t and w. The dimension of search
space of outer minimization is twice as large as it is for the
optimal trapezoid problem from previous subsection. The
optimization task is thus more difficult than in the previous
case, and gradient and Hessian of inner maximization, as
discussed in the preceding subsection, may prove even
more useful.
Examples chosen for evaluation
Five examples of hypothetical models were analyzed:
1. one-compartment linear model with first-order absorp-
tion, single dose;
2. one-compartment linear model with first-order absorp-
tion, steady state;
3. two-compartment linear model with iv bolus
administration;
4. one-compartment model with iv bolus administration
and Michaelis-Menten elimination;
5. one-compartment model with first-order absorption
and Michaelis-Menten elimination.
An interval from t1 ¼ 0 to t2 ¼ 24h was chosen for AUC.
The dosing interval (s) for model 2 also matched that
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interval: s ¼ 24h. For each model either ranges or fixed
values of parameters were assumed. They are given in
Table 1 along with the resultant AUC range. It is explained
in the Appendix why some parameters can be fixed and
which of them to choose.
Three levels of coefficient of variation were assumed:
10%, 5% and 0% (no random error). They were combined
with three sample sizes chosen for presentation: n ¼ 2, 4
and 6. This is a range of sample sizes considered, among
others, while developing limited sampling strategies. As it
will be seen, at greater samples the difference between
different approaches becomes less evident.
Numerical methods
MATLAB 7.11 (R2011b) software (The MathWorks, Inc.)
with Minimization Toolbox [21, 22] was used to perform
the required computations. A set of M-files written for that
purpose is available as supplementary material to this
paper. In order to obtain a solution to the minimax problem
the ‘fmincon’ procedure from Minimization Toolbox was
used on two levels of recursion. This is a general-purpose
constrained nonlinear minimization procedure. It contains a
variety of optimization algorithms that can be chosen by
the user. At outer level (minimization in w and t) an active-
set optimization was chosen, the choice of which implies
application of sequential quadratic programming (SQP)
algorithm. This algorithm belongs to the quasi-Newton
family and it can perform better, if derivatives of the
objective function are available. It is explained in the
Appendix, how the gradient of maximum risk can be
computed.
At the inner level (maximization of risk in h) a trust-
region-reflective algorithm was preferred. It requires both
gradient (first-order derivatives) and Hessian (second-order
derivatives) of the objective (in this case the risk function
itself) in model parameters.
If a concentration-time dependence and AUC can be
expressed in a closed-form by model parameters, then the
exact calculation of derivatives imposes no significant
difficulty. This is the case with linear compartment models.
In the case of one-compartment nonlinear model, with
Michaelis-Menten elimination and bolus iv input,C(t) can-
not be expressed in a closed-form, but it may be repre-
sented by an implicit function. By theorem on implicit
function derivative, differentiation of C(t) in this case does
not introduce true complications either. Moreover, there is
a closed-form expression for an AUC given C(t) at integral
limits [17]. However, in order to keep the software as
simple as possible, this solution has not actually been used.
Conversely, the same solution has been applied to model 4,
as it is described just below for model 5.
Table 1 Model parameter
ranges and fixed values
Model Equation Parameter(h or AUC) Range or fixed value
1 C ¼ A eket  ekat
 
ka ½ðln 2Þ=4; 3 ln 2
ke ½ðln 2Þ=12; ðln 2Þ=4
A ¼ FDka
Vd kakeð Þ
20
AUC [56, 250]
2 C ¼ A eke t
1ekes  e
ka t
1ekas
 
ka ½ðln 2Þ=4; 3 ln 2
ke ½ðln 2Þ=12; ðln 2Þ=4
A ¼ FDka
Vd kakeð Þ
20
AUC [58, 337]
3 C ¼ A1ek1t þ A2ek2t k1 ½0:5 ln 2; 6 ln 2
k2 ½ðln 2Þ=4; ðln 2Þ=24
a ¼ A2=A1 [0.8, 1.25]
A1 10
AUC [50, 245]
4 dC
dt
¼  VmC
KMþC
KM [2, 20]
Vm [0.2, 1]
C0 ¼ Cð0Þ 10
AUC [70, 221]
5 dC
dt
¼  VmC
KMþC þ Ae
kat KM [2, 5]
Vm [0.4, 0.7]
ka ½ðln 2Þ=2; ln 2
A ¼ FDka
Vd
5
AUC [52, 232]
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For the one-compartment nonlinear model, with
Michaelis-Menten elimination and first-order input no
closed-form solution exists, and a differential equation of
the model has to be numerically solved. The MATLAB
procedure ‘ode113’, implementing a variable order Adams-
Bashforth-Moulton method was used to that purpose (for
Table 2 Properties and performance of the linear quadrature, optimal in the minimax sense, compared to the optimal trapezoid and GL or CC
approaches for Model 1
n cv½% Method
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Objective
p
Bias RMSRE Maximum deviance Maximum relative deviance
6 10 optimal 4.53E-2a .349 4.34E-
2
-36.0b -.1797
opt. trap. 4.67E-2 -.324 4.48E-
2
-35.6 -.1912
GL 5.79E-2 .741 5.12E-
2
38.8 .2203
5 optimal 2.40E-2 -.392 2.31E-
2
-18.6 -.0933
opt. trap. 2.57E-2 -.769 2.39E-
2
-19.8 -.0973
GL 3.33E-2 .641 2.61E-
2
19.5 .1015
0 optimal 2.03E-4 0.009 1.12E-
4
0.03 2.03E-4
opt. trap. 1.64E-2 -1.033 8.19E-
3
-4.08 -1.64E-2
GL 1.90E-2 0.662 6.46E-
3
1.98 1.89E-2
4 10 optimal 5.73E-2 -0.870 5.45E-
2
49.2 .2187c
opt. trap. 5.86E-2 -1.230 5.57E-
2
46.3 -.2116
CC 8.84E-2 -3.600 6.81E-
2
-47.8 -.2601
5 optimal 2.80E-2 0.041 2.65E-
2
-22.1 .1086
opt. trap. 3.26E-2 -0.860 2.88E-
2
-28.8 -.1187
CC 6.99E-2 -3.462 4.27E-
2
-27.3 -.1696
0 optimal 2.00E-3 0.003 1.03E-
3
0.49 -.0020
opt. trap. 2.13E-2 0.219 1.07E-
3
-4.22 -.0208
CC 6.26E-2 -3.896 2.96E-
3
-6.00 -.0624
2 10 optimal 0.085 -2.23 0.076 -61.1 .2943
opt. trap. 0.137 -8.42 0.109 -88.8 -.3933
GL 0.244 13.87 0.143 73.8 .5326
5 optimal 0.050 -0.049 0.039 27.3 .1626
opt. trap. 0.116 -6.693 0.073 -51.2 .2537
GL 0.225 13.948 0.118 47.7 .3716
0 optimal 0.070 -4.36 0.042 -17.4 -.0698
opt. trap. 0.108 -6.07 0.056 -26.8 -.1076
GL 0.218 13.95 0.109 21.7 .2176
a objective for the optimal method not significantly less than for the optimal trapezoid
b the maximum absolute deviance inferior for the optimal method
c the maximum relative deviance inferior for the optimal method
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detailed description of all numerical algorithms used refer to
MATLAB documentation [21, 22]). In addition to the
required C(t) values, a differential equation solver can also
yield a value of AUC along with derivatives of both C(t) and
AUC. The necessary details are given in the Appendix.
For each combination of model, sample size and cv an
optimal minimax method was found. Moreover, an optimal
trapezoid method and either Gauss-Legendre or Clenshaw-
Curtis approximation (whichever performed better) were
also found.
Table 3 Properties and performance of the linear quadrature, optimal in the minimax sense, compared to the optimal trapezoid and GL or CC
approaches for Model 2
n cv½% Method
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Objective
p
Bias RMSRE Maximum deviance Maximum relative deviance
6 10 optimal 5.19E-2 1.18 4.85E-
2
54.7 -.2273
opt. trap. 6.12E-2 -1.95 5.11E-2 52.2 -.2287
GL 5.78E-2 0.65 5.05E-
2
56.2 -.2273
5 optimal 2.27E-2 0.037 2.20E-
2
-22.5 .0877
opt. trap. 2.40E-2 -0.614 2.29E-
2
-23.3 .0920
GL 3.32E-2 0.649 2.61E-
2
26.8 .1183
0 optimal 6.37E-4 0.035 3.65E-
4
-0.21 6.37E-4
opt. trap. 7.80E-3 -0.572 4.31E-
3
-2.53 7.78E-3
GL 1.87E-2 0.675 6.04E-
3
1.98 1.86E-2
4 10 optimal 5.41E-2 0.024 5.20E-
2
51.3 .2070
opt. trap. 6.36E-2 -1.963 5.89E-
2
-68.0 -.2453
CC 8.74E-2 -3.517 6.98E-
2
66.2 -.2647
5 optimal 2.95E-2 0.32 2.84E-
2
-27.2 -.1115
opt. trap. 3.30E-2 -1.70 3.14E-
2
-32.8 -.1328
CC 6.86E-2 -3.40 4.60E-
2
-32.4 -.1739
0 optimal 1.94E-3 0.004 9.77E-
4
0.64 .0019
opt. trap. 4.41E-2 -2.702 2.09E-
2
-10.84 -.0440
CC 6.12E-2 -3.341 2.75E-
2
-5.99 -.0611
2 10 optimal 0.083 2.16 0.076 103 -.3376
opt. trap. 0.210 -0.46 0.122 108 .5854
GL 0.239 13.82 0.137 101 .5536
5 optimal 0.049 -2.31 0.041 -41.2 -.1815
opt. trap. 0.190 0.26 0.089 68.9 .3288
GL 0.219 13.75 0.109 61.3 .3652
0 optimal 0.026 1.50 0.014 8.3 .0255
opt. trap. 0.183 0.46 0.076 31.0 .1825
GL 0.212 13.77 0.043 21.6 .2115
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The trapezoid method was subject to the following
restriction: the last knot always had to be placed at the end
of the time interval. On the other hand a linear extrapola-
tion to the time zero was allowed for models with C0 [ 0.
This asymmetry was due to the fact that the trapezoid
method with a linear extrapolation to t ¼ s no longer
belongs to the LC class. An extrapolation to t ¼ 0 does not
introduce that problem [13].
Table 4 Properties and performance of the linear quadrature, optimal in the minimax sense, compared to the optimal trapezoid and GL or CC
approaches for Model 3
n cv½% Method
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Objective
p
Bias RMSRE Maximum deviance Maximum relative deviance
6 10 optimal 4.53E-2 0.787 4.30E-
2
32.7 .1712
opt. trap. 6.01E-2 -0.602 4.74E-
2
-31.2 .2071
GL 5.74E-2 -0.329 4.89E-
2
-36.9 -.1995
5 optimal 2.28E-2 0.312 2.22E-
2
15.1 .0960
opt. trap. 3.81E-2 -0.197 2.52E-
2
13.8 .1122
GL 3.32E-2 -0.334 2.48E-
2
-15.3 .1114
0 optimal 1.35E-3 0.027 6.24E-
4
0.29 -.0013
opt. trap. 3.33E-2 -0.439 1.34E-
2
3.16 .0328
GL 1.96E-2 -0.333 5.06E-
3
-0.99 -.0190
4 10 optimal 5.47E-2 0.810 5.30E-
2
-44.3 -.2187
opt. trap. 7.80E-2 -1.105 5.93E-
2
-40.4 .2808
CC 9.17E-2 1.937 6.49E-
2
40.2 .2897
5 optimal 2.84E-2 0.084 2.79E-
2
20.1 .1083
opt. trap. 5.32E-2 -0.986 3.29E-
2
-21.0 .1346
CC 6.69E-2 1.849 3.27E-
2
20.7 .1616
0 optimal 5.72E-3 0.024 2.47E-
3
1.22 .0057
opt. trap. 4.18E-2 -0.833 1.59E-
2
4.44 .0417
CC 5.62E-2 1.890 2.21E-
2
3.34 .0551
2 10 optimal 0.104 2.573 0.083 57.5 .3339
opt. trap. 0.120 -0.503 0.095 -61.1 .4148
GL 0.227 -8.866 0.122 -55.2 -.4542
5 optimal 0.075 1.948 0.046 33.6 .1917
opt. trap. 0.085 -0.130 0.052 -28.6 .2180
GL 0.218 3.908 0.104 -29.3 .3566
0 optimal 0.062 -1.174 0.021 6.76 .0603
opt. trap. 0.070 -0.042 0.026 -8.22 .0663
GL 0.215 -8.841 0.097 -13.97 -.2121
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Table 5 Properties and performance of the linear quadrature, optimal in the minimax sense, compared to the optimal trapezoid and GL or CC
approaches for Model 4
n cv½% Method
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Objective
p
Bias RMSRE Maximum deviance Maximum relative
deviance
6 10 optimal 4.52E-2 -1.117 4.39E-
2
37.1 .1821
opt. trap. 5.76E-2 0.458 4.28E-
2
33.2 .1982
GL 5.61E-2 0.073 4.50E-
2
-32.6 .1987
5 optimal 2.28E-2 -.5892 2.22E-
2
-17.7 -.0937
opt. trap. 3.39E-2 .2958 2.17E-
2
16.4 .1040
GL 2.81E-2 .0079 2.25E-
2
-16.7 .0942
0 optimal 5.05E-5 4.16E-3 2.40E-
5
.0058 -4.63E-5
opt. trap. 4.01E-3 -5.84E-2 6.66E-
4
.2843 -3.04E-3
CC 5.63E-5 -2.40E-5 2.18E-
6
-.0039 -5.15E-5
4 10 optimal 6.54E-2 1.779 5.69E-
2
42.4 .2615
opt. trap. 8.60E-2 0.488 5.59E-
2
41.3 .2950
GL 6.79E-2 0.028 5.40E-
2
42.2 .2429
5 optimal 3.32E-2 1.211 2.83E-
2
-20.5 -.1076
opt. trap. 4.43E-2 0.143 3.11E-
2
19.1 .1312
GL 3.39E-2 0.046 2.69E-
2
-23.0 -.1095
0 optimal 3.63E-4 3.82E-2 2.29E-
4
.0614 -3.59E-4
opt. trap. 6.43E-3 -1.50E-1 1.63E-
3
-.6145 -6.30E-3
GL 6.54E-4 -2.96E-4 2.58E-
5
-.0404 -5.16E-4
2 10 optimal 0.089 6.001 8.35E-
2
66.7 .3400
opt. trap. 0.103 -0.173 8.72E-
2
-68.1 .3920
GL 0.110 0.088 7.37E-
2
55.8 .3252
5 optimal 4.52E-2 3.778 4.37E-
2
33.1 .1683
opt. trap. 5.56E-2 -0.054 4.36E-
2
-31.3 -.1739
GL 6.56E-2 0.087 3.72E-
2
-28.3 .1598
0 optimal 7.01E-3 0.882 5.55E-
3
1.43 .0070
opt. trap. 2.40E-2 -0.065 2.70E-
3
2.18 .0238
GL 4.11E-2 0.041 2.04E-
3
2.77 .0393
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Simulations
In order to evaluate results, for each case 20,000 PK ran-
dom profiles were simulated. PK parameters were
uniformly drawn from their ranges. Based on them con-
centrations were calculated according to assumed models
and Gaussian random noise with assumed cv was subse-
quently applied. Using those samples a bias, a root mean
Table 6 Properties and performance of the linear quadrature, optimal in the minimax sense, compared to the optimal trapezoid and GL or CC
approaches for Model 5
n cv½% Method
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Objective
p
Bias RMSRE Maximum deviance Maximum relative
deviance
6 10 optimal 4.40E-2 -0.202 4.22E-
2
-28.3 .1559
opt. trap. 4.52E-2 -1.567 4.45E-
2
-31.1 -.1635
GL 5.54E-2 -0.030 4.85E-
2
30.3 .1881
5 optimal 2.24E-2 -0.251 2.16E-
2
-13.5 -.0876
opt. trap. 2.49E-2 -1.229 2.36E-
2
-15.2 -.0956
GL 2.77E-2 -0.019 2.40E-
2
15.5 .1110
0 optimal 4.67E-5 -0.0004 2.21E-
5
9.43E-2 4.65E-5
opt. trap. 1.47E-2 -1.3228 1.05E-
2
-2.827 1.47E-2
GL 5.03E-4 0.0133 1.45E-
4
0.026 4.90E-4
4 10 optimal 5.39E-2 0.325 5.14E-
2
-39.2 .2087
opt. trap. 6.00E-2 -2.808 5.80E-
2
-38.9 -.2236
GL 6.64E-2 0.357 5.73E-
2
-38.0 .2132
5 optimal 2.73E-2 0.641 2.65E-
2
19.1 .1082
opt. trap. 3.69E-2 -2.358 3.32E-
2
-21.6 -.1324
GL 3.54E-2 0.433 2.92E-
2
-22.3 .1142
0 optimal 6.87E-4 -0.021 3.76E-
4
0.14 6.85E-4
opt. trap. 2.61E-2 -2.271 1.80E-
2
-5.26 -2.60E-2
GL 1.42E-2 0.466 4.90E-
3
0.75 1.40E-2
2 10 optimal 0.078 0.64 0.074 -50.5 .3123
opt. trap. 0.144 -11.78 0.120 -66.4 .4163
GL 0.203 10.42 0.123 58.9 .4326
5 optimal 0.045 1.37 0.039 30.3 .1656
opt. trap. 0.128 -11.87 0.101 -48.9 -.2419
GL 0.180 10.39 0.099 40.0 .2712
0 optimal 4.02E-3 0.12 2.17E-
3
-0.88 .0040
opt. trap. 1.23E-1 -11.96 9.41E-
2
-22.93 -.1220
GL 1.72E-1 10.41 8.96E-
2
12.10 .1633
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squared relative error (RMSRE), minimum and maximum
absolute errors and their relative counterparts were
estimated.
While the present approach has been developed with
mild assumptions on statistical distribution of h and e, for
simulation purposes a particular distribution had to be
chosen. In order to perform a more demanding evaluation,
one may use for h a distribution that results in a harder test
than normal distribution or log-normal distribution, which
are usually applied. A (multidimensional) uniform distri-
bution creates the opportunity to scan a parameter space. It
is a common choice in a Monte-Carlo optimum search.
The main rationale for simulations was to investigate
those aspects of performance of optimal methods that do
not comprise the criteria of optimality. The statistical
parameters (RMSRE, bias, etc.) provide simple measures
for that purpose. In addition they facilitate a simple check
of results. The following inequality is to be expected for
any method:
RMSRE\
ffiffiffiffiffiffiffi
Obj
p
;
where Obj, the objective, is the maximum risk found at
chosen knots and weights. Moreover, in a case without
random noise, the maximum observed relative deviance
cannot be greater than the square root of the objective
unless the optimization failed. This relation may be
reversed in the presence of random error.
These inequalities are discussed in detail in the
Appendix.
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Fig. 1 Performance of the investigated methods for Model 1 with n=6 and cv ¼ 0:10. Panels depict true vs estimated AUC by (a) optimal,
(b) optimal trapezoid, and (c) Gauss-Legendre methods. Panel (d) displays knots and weights of these methods (one bar of optimal method is
hidden behind bars of other methods)
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Results
The results of the optimum method search and the related
simulations are compiled in Tables 2, 3, 4, 5, and 6.
Footnote labels in the body of Table 2 are referred to in the
Discussion. They indicate examples of specific behaviour
of results.
A few representative plots showing the quality of the
predictions can be found in Figs. 1, 2, and 3. These plots
show each simulated case as a small gray dot. Its abscissa
equals to the true AUC value, i.e. calculated based on PK
parameters values assumed in the simulation, and its
ordinate represents the result of estimation. As it is quite
common that maximum risk is reached at the extremal
values of some or all parameters the special points simu-
lated for these extremal values are indicated by open square
symbols (h). Open triangles indicate those points at which
the maximum estimation error appeared: / and . are for
maximum relative under- and overestimates, respectively;
while O and M are for maximum absolute under- and
overestimated results in a plot. In these figures, on separate
plots, the knots and weights of all three methods are also
depicted. The position of each bar is that of a knot while its
height represents a value of weight.
Figure 4 contains sample spaghetti plots for all models
at cv ¼ 0:1 and n ¼ 4. Each 200th PK profile (of 20,000) is
shown along with the corresponding concentrations mea-
sured at knots of investigated methods. Yet another manner
of comparison of methods is displayed in Fig. 5. It contains
a ‘‘mean’’ profile for Model 1, i.e. a profile simulated at
midpoint values of PK parameters. The symbols are plotted
at knots of the corresponding methods. The area covered by
each symbol is proportional to its contribution to the total
AUC.
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Fig. 2 Performance of the investigated methods for Model 2 with n=2 and cv ¼ 0:05. Panels depict true vs estimated AUC by (a) optimal,
(b) optimal trapezoid, and (c) Gauss-Legendre methods. Panel (d) displays knots and weights of these methods
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Discussion
The objective for the optimal method was not always sig-
nificantly less than for the optimal trapezoid (Table 2, foot-
note a). For a richer sampling (n ¼ 6) and higher variability
(cv ¼ 0:1) the maximum risk of all methods was comparable:
the objective of the optimal method was never lower than
30% of the worst method’s objective. On the other hand for
cv ¼ 0 the objectives differed to even more than five orders
of magnitude. Differences also appeared to be more pro-
nounced with a decrease in the sample size. It can also be
confirmed by inspection of the Figures: patterns on Fig. 1
(richer sampling, higher variability) are rather similar across
all three methods, while on Fig. 2 (very sparse sampling) and
Fig. 3 (no variability, in addition) patterns are quite different.
Several maximum absolute deviances appeared to be
inferior for the optimal method (Table 2, footnote b).
Furthermore, it happened that the maximum relative devi-
ance observed was worse for an optimal method than for one
of the other methods (Table 2, footnote c). There was no
contradiction in this, since the neighbourhood of such h, at
which other methods would perform worse than the optimal
one, might simply has been missing in the simulation.
There was no clear superiority of either bias or RMSRE
for the optimal method in comparison to other methods.
Also, one cannot clearly indicate which one of the alter-
native methods had lower risk across the investigated
models.
Even for as large a sample as n ¼ 6, the maximum
relative deviance was of order of 20% for any method at
cv ¼ 0:10. Assuming the deviance of 20% is at the limit of
usefulness, it could be provided in most cases also for n ¼
2 and cv ¼ 0:05 using the optimal method with relative
risk.
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Fig. 3 Performance of the investigated methods for Model 2 with n=2 and cv ¼ 0 (no random error). Panels depict true vs estimated AUC by
(a) optimal, (b) optimal trapezoid, and (c) Gauss-Legendre methods. Panel (d) displays knots and weights of these methods
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Fig. 4 Spaghetti plots for n ¼ 4 and cv ¼ 0:05 across models 1–5
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Inequality 18 discussed in the Appendix was satisfied for
samples with cv [ 0, confirming that random errors out-
weigh quadrature errors. For samples with cv ¼ 0 inequality
17 was satisfied, indicating successful optimization.
The precise definition of the optimal AUC estimation
method depends on the choice of risk function, considered
class of quadratures, and the interpretation of the PK
parameters vector (Bayesian or minimax estimation). The
present paper contains an analysis of the specific combi-
nation of these factors: quadratic loss function, LC
quadratures, and minimax estimator. It was demonstrated
how much progress may be made by transition from the
simple trapezoid method to the optimal LC quadrature in
the above sense.
That LC-quadratures are distinguished may be argued as
follows: In the framework of linear pharmacokinetics they
guarantee linearity of the AUC estimates. With non-linear
quadratures the calculation of risk function can be quite dif-
ficult and it may require full knowledge of probability distri-
bution of random errors. Also, an application of numerical
integration algorithms, including Monte-Carlo, might be
necessary. Likewise, the minimax approach enables more
general treatment than the Bayesian framework, since the
latter depends on the prior distribution of model parameters,
which is not necessarily known. On the other hand, in order to
successfully apply the present method, the appropriate PK
model has to be identified beforehand and the range of certain
PK parameters as well as cv should be estimated.
Thus prior investigation of the drug on the target pop-
ulation is required. Along with observed clearer superiority
on small samples it suggests that developing of limited
sampling strategies may constitute an area of application
for this approach.
At this point one may wonder, why not simply fit the
model to the data and use obtained PK parameters to cal-
culate AUC? Although it is possible in principle, it is an
indirect solution, and as such it does not need to be optimal.
To illustrate this the following analogy can be developed:
Gauss-Legendre quadrature of order n (i.e. having n
knots) is exact for any polynomial of an order up to 2n 1.
For instance, if a polynomial value is known at three
properly chosen knots, this polynomial can be exactly
integrated, provided its order is 5 or less. But no polyno-
mial coefficients can be determined for polynomials of an
order  3. In fact, there is a continuum of polynomials,
passing through those given points, with the same integral;
a few of them are depicted in Figure 6.
While it is believed that the case discussed herein is an
important one, it is by no means the only one that deserves
analysis. In particular, non-linear quadratures are certainly
worth investigation, despite the difficulties indicated above,
as they are more general. The widely used log-trapezoid rule
is a very simple instance of such a quadrature.
The AUC in the finite interval is more appropriate to the
steady state. Amisaki gives an important insight into the
problem of integration in the infinite interval [23]; this
topic also appears to be worth further analysis.
Conclusions
Optimal linear minimax estimator of AUC in the finite
interval can be effectively constructed for PK models,
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regardless of whether they are given by an explicit
C(t) relationship or defined by the differential equations.
The developed method may also be applied in other dis-
ciplines, where estimation of integrals from sparse and
noisy data is essential.
The optimal method may appear significantly better than
other considered methods for low variability samples. On
the other hand, for larger samples with higher variability it
is less advantageous and it may be replaced by the simpler
method. In particular, GL and CC algorithms may then be
considered, since their weights and knots do not depend on
the model nor the range of model parameters.
There is no optimal AUC estimator in the universal
sense, but what is meant by ’optimal’ depends on so many
factors that it appears that the answer to the question in the
title should be positive.
The benefits of the minimax estimator with the LC
quadrature and constant cv may be summarized as follows:
1. To obtain the estimator one does not need to know PK
parameters distribution; no covariance matrix is nec-
essary. Only a reasonable range of parameters should
be determined.
2. Detailed knowledge on experimental error is also
unimportant. Zero mean and constant cv conditions
suffice.
3. A construction of the estimator does not involve
multidimensional integrals and their numerical
approximations.
4. A constant cv condition with a relative risk simplifies
the estimator construction process, even for nonlinear
models. This is discussed in the first subsection of the
Appendix.
5. In a sense, this estimator is more conservative than the
Bayesian approach, since it minimizes an error in the
worst possible scenario and not in an average situation
as does the Bayesian approach.
As a closing remark a comment on the methodology
being used for elaborating limited-sampling strategy for a
number of drugs [6, 8–10] can be given. Formally, the
applied quadrature differs from the LC type only by an
additional constant term (the intercept), but the inter-
pretation is quite different. Linear regression is postu-
lated between AUC and concentrations measured at
knots. The weights have the meaning of multiple
regression coefficients. It might appear, that some kind of
maximum likelihood estimator of AUC is constructed in
this way. Note however, that postulate of linear depen-
dency is not necessarily true in PK applications. The
present paper also uses linear quadrature, but does not
assume it is exact in the absence of random errors, as the
linear regression approach does.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Appendix
Reducing the search space
General considerations
Consider two parameter vectors, h and h0, both in the assumed
parameter range, such that there exists j so that for any t
Cðt; h0Þ ¼ jCðt; hÞ: ð9Þ
Then, in the case of constant cv, Rðh0Þ ¼ j2RðhÞ and
Rrðh0Þ ¼ RrðhÞ.
Thus, if there exists a subset H0, of the parameter range
H, such that for any h in H there exists h0 in H0 so that
Eq. 9 holds with j 1, then the search space H can be
reduced to H0.
From practical reasons H is chosen as a multidimen-
sional interval (or combination of such intervals):
H ¼ h : hmin;i hi hmax;i; i ¼ 1. . . dimðhÞ
	 

If H0 can be chosen so that for some i, hi is fixed, then a
dimension of search space will be reduced. This may sig-
nificantly decrease the computing time.
Application to PK models
In the case of linear PK models Eq. 9 is satisfied auto-
matically. For models 1 and 2 let the parameter range be
chosen as
H ¼ ½ka min; ka max  ½ke min; ke max  ½Amin;Amax
and H0 as
H0 ¼ ½ka min; ka max  ½ke min; ke max  fAmaxg:
For model 3 the choices might be
H ¼½k1 min; k1 max  ½k2 min; k2 max  ½Amin;Amax
 ½pmin; pmax
and
H0 ¼½k1 min; k1 max  ½k2 min; k2 max  fAmaxg
 ½pmin; pmax:
For model 4 one can write
dðjCÞ
dt
¼ j VmC
KM þ C
¼ ðjVmÞðjCÞ
jKM þ jC
:
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This implies that if CðtÞ is a solution of model equation
with parameters KM and Vm and initial condition
Cð0Þ ¼ C0, then jCðtÞ is a solution of the same equation
with model parameters (including initial concentration)
multiplied by j. It may be viewed as a result of change in
mass unit by factor j. If one chooses H0 as
H0 ¼½kKM min;KM max  ½kVm min;Vm max
 fC0 maxg
where k ¼ C0 min=C0 max, then the choice for H might be
H ¼H0 [ ½KM min;KM max  ½Vm min;Vm max
 ½C0 min;C0 max:
Finally, for model 5 one obtains
H0 ¼½kKM min;KM max  ½kVm min;Vm max
 ½ka min; ka max  fAmaxg
and
H ¼ H0[½KM min;KM max  ½Vm min;Vm max
 ½ka min; ka max  ½Amin;Amax:
Outer objective derivative derivation
Let MðxÞ ¼ maxh Rðh;xÞ, where x is a vector combined
from t and w. The hðmÞ that maximizes R clearly depends on
x, so one can write:
MðxÞ ¼ R hðmÞðxÞ;x
 
Thus
dMðxÞ
dxk
¼
XdimðhÞ
i¼1
oR
ohðmÞi
dhðmÞi
dxk
þ oR
oxk
If at the maximizer oR
ohðmÞ
i
6¼ 0, it implies that hðmÞi must be at
one of its bounds. Assuming that oR
ohðmÞ
i
is continuous in x, it
will remain non-zero after an infinitesimal change in xk
and therefore the maximizer will remain at its bound. It
means that
ohðmÞ
i
oxk
¼ 0. A maximizer may also be in the
interior of H implying that oR
ohðmÞ
i
¼ 0. In any case
oR
ohðmÞi
ohðmÞi
oxk
¼ 0
and
dMðxÞ
dxk
¼ oR
oxk
Treatment of models defined by differential equations
In order to obtain AUC along with CðtÞ as well as their
derivatives in parameters the model differential equation
dCðt; hÞ
dt
¼ f C t; hð Þ; h; tð Þ ð10Þ
has to be supplemented with additional equations, the first
of them being:
dAUCðt; hÞ
dt
¼ Cðt; hÞ; ð11Þ
where AUCðt; hÞ is calculated in the time interval from 0 to
t.
Define:
giðt; hÞ ¼
dCðt; hÞ
dhi
Giðt; hÞ ¼
dAUCðt; hÞ
dhi
hijðt; hÞ ¼
d2Cðt; hÞ
dhidhj
Hijðt; hÞ ¼
d2AUCðt; hÞ
dhidhj
Then
dgi
dt
¼ d
dhi
dC
dt
¼ d
dhi
f C t; hð Þ; h; tð Þ
¼ of
oC
dC
dhi
þ of
ohi
what may be written as the subsequent equations:
dgi
dt
¼ of
oC
gi þ
of
ohi
ð12Þ
and, in the similar way:
dGi
dt
¼ gi ð13Þ
Finally, for the Hessian one obtains:
d
dt
d2C
dhidhj
¼ d
2
dhidhj
dC
dt
¼ d
2
dhidhj
f C t; hð Þ; h; tð Þ
which yields the following equations:
dhij
dt
¼ o
2f
oC2
gigj þ
o2f
oCohi
gj þ
o2f
oCohj
giþ
þ of
oC
hij þ
o2f
ohiohj
ð14Þ
and
dHij
dt
¼ hij ð15Þ
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The differential Eqs. (10 – 15) with initial conditions:
Cð0; hÞ ¼ C0ðhÞ;
AUCð0; hÞ ¼ 0;
gið0; hÞ ¼
oC0
ohi
;
Gið0; hÞ ¼ 0;
hijð0; hÞ ¼
o2C0
ohidhj
;
Hijð0; hÞ ¼ 0;
if solved, form the complete data needed by the optimi-
zation procedure.
In the case of iv administration, if C0 is chosen as a
model parameter (along with KM and Vm), so that h ¼
ðKM ;Vm;C0Þ then
f ðC; h; tÞ ¼  VmC
KM þ C
and
oC0
oh
¼ ð0; 0; 1Þ
For the first-order absorption with no initial concentration
h ¼ ðKM;Vm; ka;AÞ where A ¼ FDka=Vd
f ðC; h; tÞ ¼  VmC
KM þ C
þ A exp katð Þ
and
oC0
oh
¼ ð0; 0; 0; 0Þ
Inequalities
In practice, the expectation of a random variate is always
less than its maximal possible value. In most cases it
should also be less than the maximum value observed, even
for a sample of moderate size. Thus the following
inequality must hold:
EhRrðhÞ\ max
h
RrðhÞ ð16Þ
and also, almost certainly:
max
h sample
RrðhÞ ¼ max
h sample
EeLrðQ̂; hÞ
 max
h sample
e sample
LrðQ̂; hÞ: ð17Þ
On the other hand, randomly drawn vectors h may miss the
maximizer:
max
h
RrðhÞ max
h sample
RrðhÞ: ð18Þ
MSRE estimates an expectation of the risk and for a large
sample it should provide a good approximation. On aver-
age, inequality 16 should also hold for expectation replaced
by MSRE. The relation between objective and maximum
observed loss is more complicated, because inequalities 17
and 18 work in opposite directions. If the coefficient of
variation cv is very small, or there is no random error at all,
the inequality in 17 may be replaced by an equal sign and
inequality 18 becomes important. In a more realistic situ-
ation and with a sample large enough one may expect that
random error will dominate the quadrature error, as Katz
and D’Argenio pointed out. Then inequality 17 should
prevail.
Taking square roots of these inequalities one may
summarize them as
RMSRE\
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ObjðhðmÞÞ
q
\ max
h sample
e sample
jAUC  Q̂j
AUC ð19Þ
unless the cv is 0 or very small, in which case the second
inequality sign may be reversed.
Supplementary material
Additional documentation to this paper is available as
electronic supplementary material. It consists of a set of
Matlab M-files implementing minimax optimization, and
plots of all simulations for Model 1. There are also several
sample job configuration files used by a Matlab code.
Interested readers may modify the Matlab code and/or
configuration files to develop their own models.
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